Basic Study
Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 2129-2148
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2129
Table 1 Relationship between BRAFV600E mutation and clinicopathological parameters in colorectal cancer
Variable
Cases (%)
BRAFV600E mutation
P value
Yes (%)
No (%)
Gender
Male18 (60)6 (60)12 (60)0.326
Female12 (40)4 (40)8 (40)
Age (yr)
≥ 6510 (33.3)4 (40)6 (30)0.440
< 6520 (66.7)6 (60)14 (70)
Location
Right colon9 (30)2 (20)7 (35)0.345
Left colon9 (30)5 (50)4 (20)
Rectum12 (40)3 (30)9 (45)
Mucous tissue
Positive6 (20)1 (10)5 (25)0.326
Negative24 (80)9 (90)15 (75)
Differentiated degree
High/moderate differentiation20 (66.7)3 (30)17 (85)0.005a
Poor differentiation10 (33.3)7 (70)3 (15)
T stage
T24 (13.3)04 (20)0.211
T33 (10)2 (20)1 (5)
T423 (76.7)8 (80)15 (75)
TNM stage
I + II13 (43.3)2 (20)11 (55)0.074
III + IV17 (56.7)8 (80)9 (45)
Lymph node
Positive17 (56.7)8 (80)9 (45)0.074
Negative13 (43.3)2 (20)11 (55)
Nerve invasion
Positive7 (23.3)4 (40)3 (15)0.143
Negative23 (76.7)6 (60)17 (85)
Vessel carcinoma embolus
Positive3 (10)1 (10)2 (10)0.652
Negative27 (90)9 (90)18 (90)
CA19-9 (U/mL)
High12 (40)7 (70)5 (25)0.024a
Normal18 (60)3 (30)15 (75)
CEA (ng/mL)
High11 (36.7)3 (30)8 (40)0.452
Normal19 (63.3)7 (70)12 (60)
PLT count (× 109/L)
High12 (40)5 (50)7 (35)0.344
Normal18 (60)5 (50)13 (65)